SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02419287

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.

NCT02419287 Anaplastic Large Cell Lymphoma, ALK-Positive
MeSH: Lymphoma Lymphoma, Large-Cell, Anaplastic
HPO: Anaplastic large-cell lymphoma Lymphoma

1 Interventions

Name: crizotinib

Type: Drug

crizotinib


Primary Outcomes

Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria.

Time: the entire duration of the study (5 years)

Measure: Duration ORR

Time: the entire duration of the study (5 years)

Secondary Outcomes

Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment.

Time: the entire duration of the study (5 years)

Measure: Number of patients with adverse events after crizotinib treatment

Time: the entire duration of the study (5 years)

Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire

Time: the entire duration of the study (5 years)

Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib

Time: the entire duration of the study (5 years)

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 I1171N

Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---



HPO Nodes


HPO:
Anaplastic large-cell lymphoma
Lymphoma
Genes 94
BLM MYC CDKN2A KRAS MYD88 RMRP RAG1 RAG2 MALT1 MSH6 RASGRP1 LIG4 TCF4 PMS2 ICOS NRAS WAS WIPF1 CD19 MS4A1 USB1 IGH TINF2 RB1 DCLRE1C TNFSF12 RTEL1 CTC1 CD27 CD28 PIK3R1 PRF1 NTHL1 TP63 POLE HLA-DRB1 NFKB1 NFKB2 RECQL4 RAD54B CHEK2 TNFRSF13C APC MLH1 TNFRSF13B DKC1 BIRC3 XIAP CASP10 NBN PRKCD COL14A1 FOXP1 CD81 PARN NOP10 CCND1 BCL10 BCL2 MSH2 CHD7 CTLA4 ATM BCL6 MAGT1 RUNX1 TNFRSF1B XRCC4 WRAP53 PTEN MDM2 FAS NHP2 ADA FASLG CR2 SH2D1A TERC AAGAB KIT TERT NSUN2 IL2RG LYST RNF43 ZAP70 DNASE1L3 TP53 RAD54L ITK STAT3 IL7R KIF11 PNP